RU2244545C2 - Композиция пропофола с усиленным ингибированием микробов - Google Patents

Композиция пропофола с усиленным ингибированием микробов Download PDF

Info

Publication number
RU2244545C2
RU2244545C2 RU2002122394/15A RU2002122394A RU2244545C2 RU 2244545 C2 RU2244545 C2 RU 2244545C2 RU 2002122394/15 A RU2002122394/15 A RU 2002122394/15A RU 2002122394 A RU2002122394 A RU 2002122394A RU 2244545 C2 RU2244545 C2 RU 2244545C2
Authority
RU
Russia
Prior art keywords
composition
propofol
pharmaceutical composition
composition according
anesthetic pharmaceutical
Prior art date
Application number
RU2002122394/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002122394A (ru
Inventor
Джек Йонгфэнг ЗХАНГ (US)
Джек Йонгфэнг ЗХАНГ
Джи Фэй ДИНГ (US)
Джи Фэй ДИНГ
Мэри Зи-Пинг ЛУО (US)
Мэри Зи-Пинг ЛУО
Original Assignee
Амфастар Фармацевтикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амфастар Фармацевтикалз Инкорпорейтед filed Critical Амфастар Фармацевтикалз Инкорпорейтед
Publication of RU2002122394A publication Critical patent/RU2002122394A/ru
Application granted granted Critical
Publication of RU2244545C2 publication Critical patent/RU2244545C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2002122394/15A 2000-12-20 2001-07-16 Композиция пропофола с усиленным ингибированием микробов RU2244545C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 2000-12-20
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition

Publications (2)

Publication Number Publication Date
RU2002122394A RU2002122394A (ru) 2004-03-20
RU2244545C2 true RU2244545C2 (ru) 2005-01-20

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002122394/15A RU2244545C2 (ru) 2000-12-20 2001-07-16 Композиция пропофола с усиленным ингибированием микробов

Country Status (11)

Country Link
US (1) US6399087B1 (enExample)
EP (1) EP1250130A4 (enExample)
JP (1) JP2004516265A (enExample)
CN (1) CN1359677A (enExample)
AU (1) AU7592501A (enExample)
BR (1) BR0109769A (enExample)
CA (1) CA2397990A1 (enExample)
MX (1) MXPA02008097A (enExample)
RU (1) RU2244545C2 (enExample)
UA (1) UA73970C2 (enExample)
WO (1) WO2002049631A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
IL141095A0 (en) 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003286725B2 (en) * 2002-10-29 2007-07-12 Transform Pharmaceuticals, Inc. Propofol with cysteine
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
SI3311805T1 (sl) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
BRPI0615292A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2819988C (en) * 2011-01-04 2019-11-12 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
KR101903351B1 (ko) * 2011-03-04 2018-10-04 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
JP6046057B2 (ja) 2011-03-04 2016-12-14 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 経口投与用タペンタドールの水性医薬製剤
JP6027549B2 (ja) 2011-03-04 2016-11-16 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む半固形の水性医薬組成物
EP3192501B1 (en) 2011-05-25 2020-05-13 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
MX374014B (es) 2012-05-16 2020-07-24 Mewa Singh Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
BR112015004997B1 (pt) 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
EP3331567B1 (en) * 2015-07-24 2020-09-23 Neon Laboratories Ltd. Stabilized injectable emulsion of propofol and ketamine
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
BR112019012791A2 (pt) 2016-12-23 2019-12-03 Novaliq Gmbh composição oftálmica para o tratamento da doença do olho seco
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147432C1 (ru) * 1994-03-22 2000-04-20 Зенека Лимитед Эмульсии типа масло в воде, содержащие пропофол и эдетат
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141095A0 (en) * 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147432C1 (ru) * 1994-03-22 2000-04-20 Зенека Лимитед Эмульсии типа масло в воде, содержащие пропофол и эдетат
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант

Also Published As

Publication number Publication date
WO2002049631A1 (en) 2002-06-27
RU2002122394A (ru) 2004-03-20
EP1250130A1 (en) 2002-10-23
AU7592501A (en) 2002-07-01
UA73970C2 (en) 2005-10-17
US6399087B1 (en) 2002-06-04
MXPA02008097A (es) 2004-09-10
JP2004516265A (ja) 2004-06-03
CA2397990A1 (en) 2002-06-27
BR0109769A (pt) 2003-02-04
EP1250130A4 (en) 2006-03-15
CN1359677A (zh) 2002-07-24

Similar Documents

Publication Publication Date Title
RU2244545C2 (ru) Композиция пропофола с усиленным ингибированием микробов
KR100861820B1 (ko) 미생물 특성이 증진된 프로포폴 제제
EP1124536B1 (en) Propofol composition comprising pentetate
EP1052975B1 (en) Propofol composition containing sulfite
CA2367093A1 (en) Propofol formulation containing tris
CA2366799A1 (en) Propofol compositions containing preservative additives
AU2001275925B2 (en) Propofol formulation with enhanced microbial inhibition
US20070293586A1 (en) Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
MXPA01004004A (en) Propofol composition comprising pentetate

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070717